Sanders Morris Harris LLC bought a new position in shares of GSK PLC Sponsored ADR (NYSE:GSK – Free Report) in the third quarter, HoldingsChannel reports. The firm bought 28,800 shares of the pharmaceutical company’s stock, valued at approximately $1,404,000.
Other institutional investors and hedge funds also recently modified their holdings of the company. Nvest Financial LLC acquired a new stake in shares of GSK in the second quarter valued at approximately $2,236,000. Kahn Brothers Group Inc. purchased a new position in shares of GSK during the 2nd quarter worth approximately $8,305,000. Keystone Financial Planning Inc. raised its position in shares of GSK by 3,114.8% during the 2nd quarter. Keystone Financial Planning Inc. now owns 195,590 shares of the pharmaceutical company’s stock worth $10,253,000 after purchasing an additional 189,506 shares during the last quarter. NewEdge Advisors LLC raised its position in shares of GSK by 842.9% during the 2nd quarter. NewEdge Advisors LLC now owns 953,574 shares of the pharmaceutical company’s stock worth $49,986,000 after purchasing an additional 852,437 shares during the last quarter. Finally, Baird Financial Group Inc. lifted its stake in GSK by 110.3% in the 2nd quarter. Baird Financial Group Inc. now owns 50,129 shares of the pharmaceutical company’s stock valued at $2,628,000 after buying an additional 26,290 shares in the last quarter. Hedge funds and other institutional investors own 15.74% of the company’s stock.
GSK News Summary
Here are the key news stories impacting GSK this week:
- Positive Sentiment: Cost savings could support profitability: GSK reportedly plans to eliminate up to 1,217 jobs in Belgium as part of a three-year restructuring program. While the cuts create near-term disruption, investors may view them as a step toward improving efficiency and controlling costs. GSK to cut up to 1,217 jobs in Belgium, L’Echo says
- Positive Sentiment: Pipeline progress: The first patient has been dosed in a GSK and Oxford University trial evaluating a potential treatment for ulcerative colitis. The study adds to the company’s longer-term growth prospects, although clinical and regulatory risks remain. First Patient Dosed in GSK-Oxford Colitis Trial
- Positive Sentiment: Expanded U.S. manufacturing presence: GSK plans to invest $800 million in a Pennsylvania expansion, potentially strengthening domestic production capacity and supporting future operational growth. GSK to invest $800M in Pennsylvania expansion
- Neutral Sentiment: Third-quarter outlook remains broadly steady: RBC Capital Markets expects results to be roughly in line, with weaker vaccine sales offset by strength in HIV medicines and respiratory drug Nucala. RBC maintained its Sector Perform rating and 1,975-pence price target ahead of the October 28 earnings release. GSK third quarter likely to be in line
- Negative Sentiment: Large-scale job cuts highlight restructuring pressure: The Belgian reductions, reportedly affecting more than 1,200 positions at a major vaccine operation, could raise concerns about business momentum, employee relations and execution risk. They also underscore pressure to offset softer vaccine demand. Pharmaceutical giant GSK to eliminate 1,200 jobs in Belgium
GSK Trading Up 3.6%
GSK (NYSE:GSK – Get Free Report) last announced its earnings results on Tuesday, July 28th. The pharmaceutical company reported $1.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.27 by $0.09. GSK had a net margin of 14.56% and a return on equity of 43.23%. The firm had revenue of $11.14 billion for the quarter, compared to analyst estimates of $11.02 billion. During the same quarter last year, the business earned $0.47 earnings per share. GSK’s revenue was up 5.3% compared to the same quarter last year. GSK has set its FY 2026 guidance at 4.900-5.000 EPS. As a group, analysts anticipate that GSK PLC Sponsored ADR will post 4.78 earnings per share for the current fiscal year.
GSK Increases Dividend
The firm also recently declared a quarterly dividend, which was paid on Thursday, October 8th. Shareholders of record on Friday, August 14th were issued a $0.4515 dividend. This is a boost from GSK’s previous quarterly dividend of $0.44. The ex-dividend date was Friday, August 14th. This represents a $1.81 annualized dividend and a yield of 3.8%. GSK’s payout ratio is presently 55.31%.
Analyst Upgrades and Downgrades
A number of equities research analysts have commented on the company. HSBC reiterated a “hold” rating on shares of GSK in a report on Thursday, September 10th. Barclays reissued a “sell” rating on shares of GSK in a research report on Monday, September 7th. Deutsche Bank Aktiengesellschaft reissued a “neutral” rating on shares of GSK in a report on Tuesday, September 29th. The Goldman Sachs Group restated a “neutral” rating on shares of GSK in a research report on Monday, June 29th. Finally, Weiss Ratings lowered GSK from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Wednesday, July 29th. Four equities research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and three have given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $55.33.
Check Out Our Latest Stock Report on GSK
About GSK
GSK plc is a global biopharmaceutical company headquartered in Brentford, England. The company develops and commercializes medicines and vaccines, with research and commercial activities focused on infectious diseases, respiratory conditions, immunology, oncology and HIV. Its products are distributed across markets worldwide through healthcare providers, public health systems and pharmacies.
GSK’s portfolio includes vaccines such as Shingrix for shingles and Arexvy for respiratory syncytial virus (RSV), as well as specialty medicines including Trelegy for chronic respiratory disease and Nucala for severe asthma and related inflammatory conditions.
Read More
- Five stocks we like better than GSK
- Tesla Wants to Make Its Own Chips—What Could Go Wrong?
- IREN Limited’s AI Pivot Gains Traction—But Can Its Data Centers Deliver?
- PBF Energy’s Stunning Rally Faces a Critical Test
- Citi Stock Falls Despite Earnings Beat: What Investors Need to Know
Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GSK PLC Sponsored ADR (NYSE:GSK – Free Report).
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.
